Literature DB >> 17368950

Biomarkers for early detection of breast cancer: what, when, and where?

Victor V Levenson1.   

Abstract

Early detection of breast cancer reduces the suffering and cost to society associated with the disease. A sensitive assay to identify biomarkers that can accurately diagnose the onset of breast cancer using non-invasively collected clinical specimens is ideal for early detection. The earlier and more accurate the diagnostic biomarker can predict disease onset, the more valuable it becomes. Here, a brief review of existing and emerging approaches for breast cancer biomarker identification and analysis is presented. Those biomarkers found in biological fluids, blood in particular, apparently hold the best promise for fast development of screening assays. Autoantibodies and abnormal tumor-specific DNA methylation found in cell-free plasma DNA may provide the best opportunity for constructing multiplexed and highly redundant tests, which will be sufficiently specific and sensitive for early detection of breast cancer. It is expected that technologies developed for breast cancer detection will be useful for other types of cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17368950     DOI: 10.1016/j.bbagen.2007.01.017

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  42 in total

1.  Multiplexed cancer biomarker detection using quartz-based photonic crystal surfaces.

Authors:  Cheng-Sheng Huang; Vikram Chaudhery; Anusha Pokhriyal; Sherine George; James Polans; Meng Lu; Ruimin Tan; Richard C Zangar; Brian T Cunningham
Journal:  Anal Chem       Date:  2011-12-29       Impact factor: 6.986

Review 2.  The epigenetics of breast cancer.

Authors:  Jovana Jovanovic; Jo Anders Rønneberg; Jörg Tost; Vessela Kristensen
Journal:  Mol Oncol       Date:  2010-04-29       Impact factor: 6.603

3.  DNA methylation in pre-diagnostic serum samples of breast cancer cases: results of a nested case-control study.

Authors:  Jennifer D Brooks; Paul Cairns; Roy E Shore; Catherine B Klein; Isaac Wirgin; Yelena Afanasyeva; Anne Zeleniuch-Jacquotte
Journal:  Cancer Epidemiol       Date:  2010-12       Impact factor: 2.984

4.  The promoter methylation status and mRNA expression levels of CTCF and SIRT6 in sporadic breast cancer.

Authors:  Da Wang; Changlong Li; Xuemei Zhang
Journal:  DNA Cell Biol       Date:  2014-05-19       Impact factor: 3.311

5.  Proteomic Profiling of Invasive Ductal Carcinoma (IDC) using Magnetic Beads-based Serum Fractionation and MALDI-TOF MS.

Authors:  Juan Yang; Jiang Zhu; Kang He; Ling-Yu Zhao; Li-Ying Liu; Tu-Sheng Song; Chen Huang
Journal:  J Clin Lab Anal       Date:  2014-08-17       Impact factor: 2.352

6.  Promoter hypermethylation may be an important mechanism of the transcriptional inactivation of ARRDC3, GATA5, and ELP3 in invasive ductal breast carcinoma.

Authors:  Da Wang; Peng-Na Yang; Jin Chen; Xian-Yao Zhou; Qiu-Jun Liu; Hong-Jiang Li; Chang-Long Li
Journal:  Mol Cell Biochem       Date:  2014-08-23       Impact factor: 3.396

7.  Breast cancer and protein biomarkers.

Authors:  Lay-Harn Gam
Journal:  World J Exp Med       Date:  2012-10-20

Review 8.  Development of multifunctional nanoparticles for targeted drug delivery and noninvasive imaging of therapeutic effect.

Authors:  Hari Krishna Sajja; Michael P East; Hui Mao; Y Andrew Wang; Shuming Nie; Lily Yang
Journal:  Curr Drug Discov Technol       Date:  2009-03

Review 9.  Promoter methylation and the detection of breast cancer.

Authors:  Jennifer Brooks; Paul Cairns; Anne Zeleniuch-Jacquotte
Journal:  Cancer Causes Control       Date:  2009-11       Impact factor: 2.506

10.  The multiplex bead array approach to identifying serum biomarkers associated with breast cancer.

Authors:  Byoung Kwon Kim; Jong Won Lee; Pil Je Park; Yong Sung Shin; Won Young Lee; Kyung Ae Lee; Sena Ye; Heesun Hyun; Kyung Nam Kang; Donghwa Yeo; Youngdai Kim; Sung Yup Ohn; Dong Young Noh; Chul Woo Kim
Journal:  Breast Cancer Res       Date:  2009-04-28       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.